Quantification of HBG mRNA in primary erythroid cultures: Prediction of the response to hydroxyurea in sickle cell and beta-thalassemia

European Journal of Haematology

Volumn 92, Issue 1, 2014, Pages 66-72

  Pecoraro, Alice ^a   Rigano, Paolo ^a   Troia, Antonio ^a   Calzolari, Roberta ^a   Scazzone, Concetta ^b   Maggio, Aurelio ^a   Steinberg, Martin H ^c   Marzo, Rosalba Di ^a  

^a AO Ospedali Riuniti Villa Sofia Cervello   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

thalassemia; Hydroxyurea; Liquid erythroid cultures; Real time quantitative PCR; Sickle cell disease

Indexed keywords

GLOBIN MESSENGER RNA; HEMOGLOBIN F; HEMOGLOBIN VARIANT; HYDROXYUREA;

ADULT; ARTICLE; BETA THALASSEMIA; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG MEGADOSE; ERYTHROCYTE CULTURE; ERYTHROID PRECURSOR CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SICKLE CELL ANEMIA; THALASSEMIA INTERMEDIA; TREATMENT RESPONSE;

HYDROXYUREA; LIQUID ERYTHROID CULTURES; REAL-TIME QUANTITATIVE PCR; SICKLE CELL DISEASE; Β-THALASSEMIA;

ADULT; AGED; ANEMIA, SICKLE CELL; BETA-THALASSEMIA; ERYTHROID PRECURSOR CELLS; FEMALE; FETAL HEMOGLOBIN; GAMMA-GLOBINS; GENE EXPRESSION; HUMANS; HYDROXYUREA; MALE; MIDDLE AGED; PRIMARY CELL CULTURE; RNA, MESSENGER; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890192413     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12204     Document Type: Article

References (47)

1. Borgna-Pignatti C, Gamberini MR. Complications of thalassemia major and their treatment. Exp Rev Hematol 2011;4:353-66.
2. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-93.
3. Steinberg MH, Rodgers GP. Pharmacologic modulation of fetal haemoglobin. Medicine 2001;80:328-44.
4. Perrine SP. Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. Pediatr Ann 2008;37:340-6.
5. Lal A, Vichinsky E. The role of fetal hemoglobin-enhancing agents in thalassemia. Semin Hematol 2004;41:17-22.
6. Olivieri NF. Reactivation of fetal hemoglobin in patients with beta-thalassemia. Semin Hematol 1996;33:24-42.
7. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995;332:1317-22.
8. Rigano P, Rodgers GP, Renda D, Renda MC, Aquino A, Maggio A. Clinical and hematological responses to hydroxyurea in sicilian patients with HbS/beta-thalassemia. Hemoglobin 2001;25:9-17.
9. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003;289:1645-51.
10. Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 2010;115:2354-63.
11. Steinberg MH, McCarthy WF, Castro O, et al. and Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia and MSH Patients' Follow-Up. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol 2010; 85:403-8.
12. Taher AT, Mussallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, Saned MS, El-Chafic AH, Fasulo MR, Cappellini MD. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 2010;115:1886-92.
13. Rigano P, Pecoraro A, Calzolari R, Troia A, Acuto S, Renda D, Restivo Pantalone G, Maggio A, Di Marzo R. Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients. Br J Haematol 2010;151:509-15.
14. Covas DT, De Lucena Angulo I, Vianna Bonini Palma P, Zago MA. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia. Haematologica 2004;89:273-80.
15. Styles LA, Lubin B, Vichinsky E, Lawrence S, Hua M, Test S, Kuypers F. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood 1997;89:2554-9.
16. Hillery CA, Du MC, Wang WC, Scott JP. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. Br J Haematol 2000;109:322-7.
17. Cokic VP, Beleslin-Cokic BB, Tomic M, Stojilkovic SS, Noguchi CT, Schechter AN. Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells. Blood 2006;108:184-91.
18. Bridges KR, Barabino GD, Brugnara C, et al. A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. Blood 1996;88:4701-10.
19. Lebensburger JD, Pestina TI, Ware RE, Boyd KL, Persons DA. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica 2010;95:1599-603.
20. Veith R, Galanello R, Papayannopoulou T, Stamatoyannopoulos G. Stimulation of F-cell production in patients with sickle-cell anemia treated with cytarabine or hydroxyurea. N Engl J Med 1985;313:1571-3.
21. Blau CA, Constantoulakis P, al-Katti A, Spadaccino E, Goldwasser E, Papayannopoulou T, Stamatoyannopoulos G. Fetal hemoglobin in acute and chronic states of erythroid expansion. Blood 1993;81:227-33.
22. Stamatoyannopoulos G. Control of globin gene expression during development and erythroid differentiation. Exp Hematol 2005;33:259-71.
23. Calzolari R, Pecoraro A, Borruso V, Troia A, Acuto S, Maggio A, Di Marzo R. Induction of gamma-globin gene transcription by hydroxycarbamide in primary erythroid cell cultures from Lepore patients. Br J Haematol 2008;141:720-7.
24. Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. Blood 2003;102:1529-30.
25. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GL. Fetal hemoglobin in sickle-cell anemia: determinants of response to hydroxyurea. Blood 1997;89:1078-88.
26. Fucharoen S, Siritanaratkul N, Winichagoon P, et al. Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. Blood 1996;87:887-92.
27. Charache S, Dover GJ, Moore RD, Eckert S, Ballas SK, Koshy M, Milner PF, Orringer EP, Phillips G Jr, Platt OS. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood 1992;79:2555-65.
28. Rodgers GP, Dover GJ, Noguchi CT, Schechter AN, Nienhuis AW. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. N Engl J Med 1990;322:1037-45.
29. Charache S, Dover GJ, Moyer MA, Moore JW. Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood 1987;69:109-16.
30. Di Marzo R, Acuto S, Calzolari R, Maggio A. Allele-specific transcription of fetal genes in primary erythroid cell cultures from Lepore and deltabeta degrees thalassemia patients. Exp Hematol 2005;33:1363-70.
31. Quentmeier H, Zaborski M, Drexler HG. The human bladder carcinoma cell line 5637 constitutively secretes functional cytokines. Leuk Res 1997;21:343-50.
32. Fabricius E, Rajewsky F. Determination of hydroxyurea in mammalian tissues and blood. Rev Eur Etud Clin Biol 1971;16:679-83.
33. Wang M, Tang DC, Liu W, Chin K, Zhu JG, Fibach E, Rodgers GP. Hydroxyurea exerts bi-modal dose-dependent effects on erythropoiesis in human cultured erythroid cells via distinct pathways. Br J Haematol 2002;119:1098-105.
34. Smith RD, Li J, Noguchi CT, Schechter AN. Quantitative PCR analysis of HbF inducers in primary human adult erythroid cells. Blood 2000;95:863-8.
35. Ware RE, Eggleston B, Redding-Lallinger R, et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood 2002;99:10-4.
36. Ma Q, Wyszynski DF, Farrell JJ, Kutlar A, Farrer LA, Baldwin CT, Steinberg MH. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. Pharmacogenomics J 2007;7:386-94.
37. Menzel S, Garner C, Gut I, et al. A QTL influencing F cell production maps to a gene encoding a zincfinger protein on chromosome 2p15. Nat Genet 2007;39:1197-9.
38. Thein SL, Menzel S, Peng X, et al. Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults. Proc Natl Acad Sci 2007;104:11346-51.
39. Lettre G, Sankaran VG, Bezerra MA, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci 2008; 105: 11869-74.
40. Sedgewick AE, Timofeev N, Sebastiani P, So JC, Ma ES, Chan LC, Fucharoen G, Fucharoen S, Fucharoen S, Barbosa CGVardarajan BN, Vardarajan BN, Vardarajan BN, Farrer LA, Baldwin CT, Steinberg MH, Chui DH. BCL11A is a major HbF quantitative trait locus in three different populations with beta-hemoglobinopathies. Blood Cells Mol Dis 2008;41:255-8.
41. So CC, Song YQ, Tsang ST, Tang LF, Chan AY, Ma ES, Chan LC. The HBS1L-MYB intergenic region on chromosome 6q23 is a quantitative trait locus controlling fetal haemoglobin level in carriers of beta-thalassaemia. J Med Genet 2008;45:745-51.
42. Uda M, Galanello R, Sanna S, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci 2008;105:1620-5.
43. Thein SL, Menzel S. Discovering the genetics underlying foetal haemoglobin production in adults. Br J Haematol 2009;145:455-67.
44. Sankaran VG, Menne JTF, Xu J, Akie TE, Lettre G, Handel BV, Mikkola HKA, Hirsschhorn JN, Cantor AB, Orkin SH. Human Fetal Hemoglobin Expression is regulated by the developmental stage-specific repressor BCL11A. Science 2008;322:1839-42.
45. Fibach E, Burke LP, Schechter AN, Noguchi CT, Rodgers GP. Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or β-thalassemia. Blood 1993;81:1630-5.
46. Watanapokasin Y, Chuncharunee S, Sanmund D, Kongnium W, Winichagoon P, Rodgers GP, Fucharoen S. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. Exp Hematol 2005;33:1486-92.
47. Mancuso A, Maggio A, Renda D, Di Marzo R, Rigano P. Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long-term follow up. Br J Haematol 2006;133:103-8.